

FILE 'HOME' ENTERED AT 10:15:22 ON 23 MAR 2006

=> file reg
COST IN U.S. DOLLARS
SINCE FILE . TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 10:15:32 ON 23 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 MAR 2006 HIGHEST RN 877591-95-2
DICTIONARY FILE UPDATES: 21 MAR 2006 HIGHEST RN 877591-95-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "IMIQUIMOD"/CN 25
E1 1 IMIPROTHRIN-CYPERMETHRIN MIXT./CN
E2 1 IMIPROTHRIN-THIAMETHOXAM MIXT./CN
E3 1 --> IMIQUIMOD/CN
E4 1 IMIQUIMOD HYDROCHLORIDE/CN
E5 1 IMIRESTAT/CN
E6 1 IMISOPASEM MANGANESE/CN
E7 1 IMITEC X 902/CN
E8 1 IMITECH 201A/CN
E9 1 IMITERITE/CN
E10 1 IMITERITE (HGAG2S2)/CN
E11 1 IMITREX/CN
E12 1 IMITRIN 1/CN
E13 1 IMITRIN 10/CN
E14 1 IMITRIN 11/CN
E15 1 IMITRIN 12/CN
E16 1 IMITRIN 13/CN
E17 1 IMITRIN 14/CN
E18 1 IMITRIN 15/CN
E19 1 IMITRIN 16/CN
E20 1 IMITRIN 17/CN

E21 1 IMITRIN 18/CN
E22 1 IMITRIN 19/CN
E23 1 IMITRIN 2/CN
E24 1 IMITRIN 23/CN
E25 1 IMITRIN 24/CN

=> S E3
L1 1 IMIQUIMOD/CN

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
5.20 5.41

FILE 'CAPLUS' ENTERED AT 10:16:02 ON 23 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Mar 2006 VOL 144 ISS 13
FILE LAST UPDATED: 22 Mar 2006 (20060322/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 11
L2 310 L1

=> s basal cell carcinom?
155804 BASAL
29 BASALS
155819 BASAL
(BASAL OR BASALS)
2033479 CELL
1784894 CELLS
2696590 CELL
(CELL OR CELLS)
148999 CARCINOM?
L3 1666 BASAL CELL CARCINOM?
(BASAL(W) CELL(W) CARCINOM?)

=> s 13 (L) 12
L4 14 L3 (L) L2

=> s 13 and 12
L5 36 L3 AND L2

=> s cycle or schedule or regimen?
322318 CYCLE
120559 CYCLES
410438 CYCLE
(CYCLE OR CYCLES)

21263 SCHEDULE
8460 SCHEDULES
27357 SCHEDULE
(SCHEDULE OR SCHEDULES)
43190 REGIMEN?
L6 472666 CYCLE OR SCHEDULE OR REGIMEN?

=> s 16 and 14
L7 3 L6 AND L4

=> d ibib 1-3

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:802538 CAPLUS
DOCUMENT NUMBER: 141:254555
TITLE: Treatment for basal cell carcinoma
INVENTOR(S): Owens, Mary L.; Fox, Terrance L.; Ginkel, Angela M.
PATENT ASSIGNEE(S): 3M Innovative Properties Company, USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004192585	A1	20040930	US 2004-808004	20040324
PRIORITY APPLN. INFO.:			US 2003-457265P	P 20030325

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:63952 CAPLUS
DOCUMENT NUMBER: 140:121944
TITLE: The use of toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview
AUTHOR(S): Stockfleth, E.; Trefzer, U.; Garcia-Bartels, C.; Wegner, T.; Schmook, T.; Sterry, W.
CORPORATE SOURCE: Department of Dermatology, University Hospital Charite, Berlin, D-10117, Germany
SOURCE: British Journal of Dermatology, Supplement (2003), 149(66), 53-56
CODEN: BJDSA9; ISSN: 0366-077X
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:780706 CAPLUS
DOCUMENT NUMBER: 137:288669
TITLE: Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens
AUTHOR(S): Shumack, Stephen; Robinson, June; Kossard, Steven; Golitz, Loren; Greenway, Hubert; Schroeter, Arnold; Andres, Kara; Amies, Mark; Owens, Mary
CORPORATE SOURCE: Australia
SOURCE: Archives of Dermatology (2002), 138(9), 1165-1171
CODEN: ARDEAC; ISSN: 0003-987X
PUBLISHER: American Medical Association
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs 2

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:63952 CAPLUS
DOCUMENT NUMBER: 140:121944
TITLE: The use of toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview
AUTHOR(S): Stockfleth, E.; Trefzer, U.; Garcia-Bartels, C.; Wegner, T.; Schmook, T.; Sterry, W.
CORPORATE SOURCE: Department of Dermatology, University Hospital Charite, Berlin, D-10117, Germany
SOURCE: British Journal of Dermatology, Supplement (2003), 149(66), 53-56
CODEN: BJDSA9; ISSN: 0366-077X
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Basal cell carcinoma (BCC) is a subtype of nonmelanoma skin cancer (NMSC), with an increasing incidence worldwide. Currently, excision of the tumor with histol. control is the standard therapy. However, high incidence rates have led to concern about the economic burden imposed by BCC management in many countries. Imiquimod is a member of a novel class of immune response modifiers (IRM), which works by using the toll-like receptor (TLR)-7. Although the exact mode of action is so far unknown, it is suggested to induce the expression of different cytokines like interleukin (IL)-1, IL-6, IL-12, interferon (IFN)- α and tumor necrosis factor (TNF)- α , which stimulate or enhance both the innate immune system and the cell-mediated immune response. Preclin. studies have indicated the potential of this TLR-7 agonist for the treatment of precancers and tumors in humans. A number of Phase II trials have demonstrated the efficacy of imiquimod for the treatment of BCC, although the most appropriate dosing regimen is being confirmed in Phase III studies. Imiquimod 5% cream for the treatment of mainly superficial BCC appears to be an effective and well-tolerated treatment option.
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:15:22 ON 23 MAR 2006)

FILE 'REGISTRY' ENTERED AT 10:15:32 ON 23 MAR 2006
E "IMIQUIMOD"/CN 25

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 10:16:02 ON 23 MAR 2006

L2 310 S L1

L3 1666 S BASAL CELL CARCINOM?

L4 14 S L3 (L) L2

L5 36 S L3 AND L2

L6 472666 S CYCLE OR SCHEDULE OR REGIMENT?

L7 3 S L6 AND L4

=> s 16 and 15

L8 3 L6 AND L5

=> s immune response modifier

192431 IMMUNE

6 IMMUNES

192433 IMMUNE

(IMMUNE OR IMMUNES)

1520221 RESPONSE

318445 RESPONSES
1669651 RESPONSE
(RESPONSE OR RESPONSES)
36656 MODIFIER
26340 MODIFIERS
53132 MODIFIER
(MODIFIER OR MODIFIERS)
L9 199 IMMUNE RESPONSE MODIFIER
(IMMUNE (W) RESPONSE (W) MODIFIER)

=> s 19 (1) 13
L10 20 L9 (L) L3

=> s 110 and 16
L11 1 L10 AND L6

=> d ibib

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:63952 CAPLUS
DOCUMENT NUMBER: 140:121944
TITLE: The use of toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview
AUTHOR(S): Stockfleth, E.; Trefzer, U.; Garcia-Bartels, C.; Wegner, T.; Schmook, T.; Sterry, W.
CORPORATE SOURCE: Department of Dermatology, University Hospital Charite, Berlin, D-10117, Germany
SOURCE: British Journal of Dermatology, Supplement (2003), 149(66), 53-56
PUBLISHER: CODEN: BJDSA9; ISSN: 0366-077X
DOCUMENT TYPE: Blackwell Publishing Ltd.
LANGUAGE: Journal; General Review
English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 19 and 13
L12 21 L9 AND L3

=> file medline
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 27.15 32.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE -0.75 -0.75

FILE 'MEDLINE' ENTERED AT 10:18:58 ON 23 MAR 2006

FILE LAST UPDATED: 22 MAR 2006 (20060322/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s imiquimod
L13 677 IMIQUIMOD

=> s basal cell carcinom?
175166 BASAL
11 BASALS
175172 BASAL
(BASAL OR BASALS)
1990536 CELL
1798779 CELLS
2651453 CELL
(CELL OR CELLS)
419161 CARCINOM?
L14 5638 BASAL CELL CARCINOM?
(BASAL(W) CELL(W) CARCINOM?)

=> s l14 and l13
L15 106 L14 AND L13

=> s cycle or schedule or regimen?
207732 CYCLE
55037 CYCLES
244615 CYCLE
(CYCLE OR CYCLES)
96893 SCHEDULE
20459 SCHEDULES
111322 SCHEDULE
(SCHEDULE OR SCHEDULES)
105335 REGIMENT?
L16 434542 CYCLE OR SCHEDULE OR REGIMENT?

=> s l16 and l15
L17 20 L16 AND L15

=> s l17 not py>2003
1354725 PY>2003
(PY>20039999)
L18 14 L17 NOT PY>2003

=> s l18 not py>2002
1924696 PY>2002
(PY>20029999)
L19 9 L18 NOT PY>2002

=> d ibib 1-9

L19 ANSWER 1 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2002697990 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12459530
TITLE: Successful treatment of basal cell
carcinomas in a nevoid basal cell
carcinoma syndrome with topical 5%
imiquimod.
AUTHOR: Stockfleth Eggert; Ulrich Claas; Hauschild Axel; Lischner
Stephan; Meyer Thomas; Christophers Enno
CORPORATE SOURCE: Department of Dermatology of the Charite, Humboldt
University, Schumannstrasse 20/21, 10117 Berlin, Germany..
E.Stockfleth@web.de

SOURCE: European journal of dermatology : EJD, (2002 Nov-Dec) Vol. 12, No. 6, pp. 569-72.
Journal code: 9206420. ISSN: 1167-1122.

PUB. COUNTRY: France
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200303

ENTRY DATE: Entered STN: 20021217
Last Updated on STN: 20030328
Entered Medline: 20030327

L19 ANSWER 2 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2002692165 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12452875
TITLE: Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
AUTHOR: Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen M R T M
CORPORATE SOURCE: Department of Dermatology, University Hospital Charite, Humboldt University, Schumannstrasse 20-21, D-10117 Berlin, Germany.
SOURCE: The British journal of dermatology, (2002 Dec) Vol. 147, No. 6, pp. 1227-36.
Journal code: 0004041. ISSN: 0007-0963.

PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200302
ENTRY DATE: Entered STN: 20021214
Last Updated on STN: 20030214
Entered Medline: 20030213

L19 ANSWER 3 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2002466008 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12224977
TITLE: Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
AUTHOR: Shumack Stephen; Robinson June; Kossard Steven; Golitz Loren; Greenway Hubert; Schroeter Arnold; Andres Kara; Amies Mark; Owens Mary
CORPORATE SOURCE: St George Dermatology and Skin Cancer Center, Level 3, 22 Belgrave St, Kogarah, Australia 2217.. sshumack@bigpond.com
SOURCE: Archives of dermatology, (2002 Sep) Vol. 138, No. 9, pp. 1165-71.
Journal code: 0372433. ISSN: 0003-987X.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE II)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)

LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200210
ENTRY DATE: Entered STN: 20020913
Last Updated on STN: 20021017

Entered Medline: 20021016

L19 ANSWER 4 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2002438913 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12196749
TITLE: Imiquimod 5% cream for the treatment of
superficial basal cell
carcinoma: a double-blind, randomized,
vehicle-controlled study.
AUTHOR: Geisse John K; Rich Phoebe; Pandya Amit; Gross Kenneth;
Andres Kara; Ginkel Angie; Owens Mary
CORPORATE SOURCE: Solano Dermatology Associates, Vallejo, California 94589,
USA.
SOURCE: Journal of the American Academy of Dermatology, (2002 Sep)
Vol. 47, No. 3, pp. 390-8.
Journal code: 7907132. ISSN: 0190-9622.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE II)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200209
ENTRY DATE: Entered STN: 20020829
Last Updated on STN: 20020924
Entered Medline: 20020923

L19 ANSWER 5 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2002336805 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12079221
TITLE: Epithelial malignancies in organ transplant patients:
clinical presentation and new methods of treatment.
AUTHOR: Stockfleth E; Ulrich C; Meyer T; Christophers E
CORPORATE SOURCE: Department of Dermatology, Christian Albrechts University,
Kiel, Germany.
SOURCE: Recent results in cancer research. Fortschritte der
Krebsforschung. Progres dans les recherches sur le cancer,
(2002) Vol. 160, pp. 251-8.
Journal code: 0044671. ISSN: 0080-0015.
PUB. COUNTRY: Germany: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200212
ENTRY DATE: Entered STN: 20020625
Last Updated on STN: 20021217
Entered Medline: 20021212

L19 ANSWER 6 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2002229610 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11966794
TITLE: Treatment of a large superficial basal
cell carcinoma with 5% imiquimod
: a case report and review of the literature.
AUTHOR: Chen T Minsue; Rosen Ted; Orengo Ida
CORPORATE SOURCE: Baylor College of Medicine, Houston, Texas, USA.
SOURCE: Dermatologic surgery : official publication for American
Society for Dermatologic Surgery [et al.], (2002 Apr) Vol.
28, No. 4, pp. 344-6. Ref: 13
Journal code: 9504371. ISSN: 1076-0512.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200205
ENTRY DATE: Entered STN: 20020423
Last Updated on STN: 20020510
Entered Medline: 20020509

L19 ANSWER 7 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2001222213 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11312429
TITLE: Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.
AUTHOR: Marks R; Gebauer K; Shumack S; Amies M; Bryden J; Fox T L; Owens M L
CORPORATE SOURCE: Department of Dermatology, St Vincent's Hospital Melbourne and the Skin & Cancer Foundation, Victoria, Australia: (Australasian Multicentre Trial Group).
SOURCE: Journal of the American Academy of Dermatology, (2001 May) Vol. 44, No. 5, pp. 807-13.
Journal code: 7907132. ISSN: 0190-9622.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE II)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200105
ENTRY DATE: Entered STN: 20010529
Last Updated on STN: 20030403
Entered Medline: 20010524

L19 ANSWER 8 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2000040341 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10570388
TITLE: Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream.
AUTHOR: Beutner K R; Geisse J K; Helman D; Fox T L; Ginkel A; Owens M L
CORPORATE SOURCE: Department of Dermatology, University of California, San Francisco, the Department of Medicine, Sutter Solano Medical Center, Vallejo, Solano Dermatology Associates, Vallejo, CA, USA.
SOURCE: Journal of the American Academy of Dermatology, (1999 Dec) Vol. 41, No. 6, pp. 1002-7.
Journal code: 7907132. ISSN: 0190-9622.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199912
ENTRY DATE: Entered STN: 20000113
Last Updated on STN: 20020405
Entered Medline: 19991215

L19 ANSWER 9 OF 9 MEDLINE on STN
ACCESSION NUMBER: 1999370938 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10442350
TITLE: Nonsurgical therapy holds promise for basal

cell carcinoma.
AUTHOR: Anonymous
SOURCE: Oncology (Williston Park, N.Y.), (1999 Jul) Vol. 13, No. 7,
pp. 1044.
Journal code: 8712059. ISSN: 0890-9091.
PUB. COUNTRY: United States
DOCUMENT TYPE: News Announcement
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199909
ENTRY DATE: Entered STN: 19991012
Last Updated on STN: 19991012
Entered Medline: 19990927

=> d ibib abs kwic 9

L19 ANSWER 9 OF 9 MEDLINE on STN
ACCESSION NUMBER: 1999370938 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10442350
TITLE: Nonsurgical therapy holds promise for basal
cell carcinoma.
AUTHOR: Anonymous
SOURCE: Oncology (Williston Park, N.Y.), (1999 Jul) Vol. 13, No. 7,
pp. 1044.
Journal code: 8712059. ISSN: 0890-9091.
PUB. COUNTRY: United States
DOCUMENT TYPE: News Announcement
LANGUAGE: English
FILE SEGMENT: Priority Journals.
ENTRY MONTH: 199909
ENTRY DATE: Entered STN: 19991012
Last Updated on STN: 19991012
Entered Medline: 19990927

TI Nonsurgical therapy holds promise for basal cell
carcinoma.

CT DT, drug therapy
Carcinoma, Basal Cell: ME, metabolism
Carcinoma, Basal Cell: PA, pathology
Cytokines: BI, biosynthesis
Cytokines: DE, drug effects
Drug Administration Schedule
Humans

Interferons
Ointments

*Skin Neoplasms: DT, drug therapy
Skin Neoplasms: ME, metabolism
Skin Neoplasms: PA, pathology
Treatment.

RN 9008-11-1 (Interferons); 99011-02-6 (imiquimod)

=> file pctfull
COST IN U.S. DOLLARS SINCE FILE TOTAL
SESSION
FULL ESTIMATED COST ENTRY 2.87 35.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
SESSION
CA SUBSCRIBER PRICE ENTRY 0.00 -0.75

FILE 'PCTFULL' ENTERED AT 10:21:02 ON 23 MAR 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 21 MAR 2006 <20060321/UPTX>

MOST RECENT UPDATE WEEK: 200611
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE.
USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHER
DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION

>>> UPDATING OF BIBLIOGRAPHIC DATA DELAYED DUE TO DELIVERY
FORMAT CHANGES <<<

>>> FULL-TEXT UPDATES CONTINUE. PATENT NUMBER AVAILABLE FOR DISPLAY
ONLY, USE FIELD CODE FPI <<<

>>> SDI SEARCHES (ALERTS) WILL BE RESUMED WHEN BIBLIOGRAPHIC DATA
BECOME AVAILABLE <<<

=> s imiquimod
L20 485 IMIQUIMOD

=> s immune response modifier
59832 IMMUNE
2164 IMMUNES
60391 IMMUNE
(IMMUNE OR IMMUNES)
266061 RESPONSE
67030 RESPONSES
272892 RESPONSE
(RESPONSE OR RESPONSES)
33691 MODIFIER
19319 MODIFIERS
46911 MODIFIER
(MODIFIER OR MODIFIERS)
L21 231 IMMUNE RESPONSE MODIFIER
(IMMUNE(W) RESPONSE(W) MODIFIER)

=> s basal cell carcinom?
23035 BASAL
12 BASALS
23039 BASAL
(BASAL OR BASALS)
214988 CELL
186206 CELLS
244057 CELL
(CELL OR CELLS)
30202 CARCINOM?
L22 2869 BASAL CELL CARCINOM?
(BASAL(W) CELL(W) CARCINOM?)

=> s 121/ab
5894 IMMUNE/AB
1643 IMMUNES/AB
6903 IMMUNE/AB
(IMMUNE OR IMMUNES)/AB
30371 RESPONSE/AB
2596 RESPONSES/AB
32080 RESPONSE/AB
(RESPONSE OR RESPONSES)/AB
13453 MODIFIER/AB
474 MODIFIERS/AB
13820 MODIFIER/AB
(MODIFIER OR MODIFIERS)/AB
L23 37 (IMMUNE RESPONSE MODIFIER/AB)
(IMMUNE(W) RESPONSE(W) MODIFIER)/AB

=> s 123 and 122
L24 28 L23 AND L22

=> s 124 not py>2002
347751 PY>2002
L25 12 L24 NOT PY>2002

=> s cycle or schedule or regimen?
158825 CYCLE
90290 CYCLES
189675 CYCLE
(CYCLE OR CYCLES)
28237 SCHEDULE
11884 SCHEDULES
33594 SCHEDULE
(SCHEDULE OR SCHEDULES)
36444 REGIMENT?

L26 224802 CYCLE OR SCHEDULE OR REGIMENT?

=> s 126 and 125
L27 11 L26 AND L25

=> s 127 and 123
L28 11 L27 AND L23

=> s 128 and 120
L29 5 L28 AND L20

=> d ibib 1-5

L29 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2002046192 PCTFULL ED 20020624 EW 200224
TITLE (ENGLISH): THIOETHER SUBSTITUTED IMIDAZOQUINOLINES
TITLE (FRENCH): IMIDAZOQUINOLINES A SUBSTITUTION THIOETHER
INVENTOR(S): DELLARIA, Joseph F., 10423 Kilbirnie Road, Woodbury, MN
55129, US [US, US];
MERRILL, Bryon A., North 8280 1155th Street, River
Falls, WI 54022, US [US, US];
RADMER, Matthew R., 3524 McNair Drive North,
Robbinsdale, MN 55422, US [US, US]
PATENT ASSIGNEE(S): 3M INNOVATIVE PROPERTIES COMPANY, 3M Center, Post
Office Box 33427, Saint Paul, MN 55133-3427, US [US,
US], for all designates States except US;
DELLARIA, Joseph F., 10423 Kilbirnie Road, Woodbury, MN
55129, US [US, US], for US only;
MERRILL, Bryon A., North 8280 1155th Street, River
Falls, WI 54022, US [US, US], for US only;
RADMER, Matthew R., 3524 McNair Drive North,
Robbinsdale, MN 55422, US [US, US], for US only
HOWARD, MarySusans, Office of Intellectual Property
Counsel, Post Office Box 33427, Saint Paul, MN
55133-3427\$, US

AGENT:
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002046192	A2	20020613

DESIGNATED STATES
W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK

RW (ARIPO): SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
 GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 APPLICATION INFO.: WO 2001-US46697 A 20011206
 PRIORITY INFO.: US 2000-60/254,218 20001208

L29 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2002046189 PCTFULL ED 20020624 EW 200224
 TITLE (ENGLISH): ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES
 TITLE (FRENCH): IMIDAZOQUINOLINES SUBSTITUEES ARYL ETHER
 INVENTOR(S): CHARLES, Leslie J., 787 Larsen Lane, Hudson, WI 54016,
 US [US, US];
 DELLARIA, Joseph F., 10423 Kilbirnie Road, Woodbury, MN
 55129, US [US, US];
 HEPPNER, Philip D., 607D Woodduck Drive, Woodbury, MN
 55125, US [US, US];
 MERRILL, Bryon A., 8280 1155th Street North, River
 Falls, WI 54022, US [US, US];
 MICKELSON, John W., 60887 Valley View Boulevard,
 Mattawan, MI 49071, US [US, US]
 PATENT ASSIGNEE(S): 3M INNOVATIVE PROPERTIES COMPANY, 3M Center, Post
 Office Box 33427, Saint Paul, MN 55133-3427, US [US,
 US], for all designates States except US;
 CHARLES, Leslie J., 787 Larsen Lane, Hudson, WI 54016,
 US [US, US], for US only;
 DELLARIA, Joseph F., 10423 Kilbirnie Road, Woodbury, MN
 55129, US [US, US], for US only;
 HEPPNER, Philip D., 607D Woodduck Drive, Woodbury, MN
 55125, US [US, US], for US only;
 MERRILL, Bryon A., 8280 1155th Street North, River
 Falls, WI 54022, US [US, US], for US only;
 MICKELSON, John W., 60887 Valley View Boulevard,
 Mattawan, MI 49071, US [US, US], for US only
 HOWARD, Mary Susan\$, Office of Intellectual Property
 Counsel, Post Office Box 33427, Saint Paul, MN
 55133-3427\$, US

AGENT:
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002046189	A2	20020613

DESIGNATED STATES
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
 SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (ARIPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EAPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 TR
 RW (EPO): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 APPLICATION INFO.: WO 2001-US46581 A 20011206
 PRIORITY INFO.: US 2000-60/254,218 20001208

L29 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 2002046188 PCTFULL ED 20020624 EW 200224
 TITLE (ENGLISH): AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES
 TITLE (FRENCH): IMIDAZOQUINOLINES A SUBSTITUTION AMIDO ETHER
 INVENTOR(S): CROOKS, Stephen L., 82 Pine Street, Mahtomedi, MN

55115-1937, US [US, US];
GRIESGRABER, George W., 631 Crimson Leaf Court, Eagan,
MN 55123, US [US, US];
HEPPNER, Philip D., 607D Woodduck Drive, Woodbury, MN
55125, US [US, US];
MERRILL, Bryon A., 8280 1155th Street North, River
Falls, WI 54022, US [US, US]
PATENT ASSIGNEE(S): 3M INNOVATIVE PROPERTIES COMPANY, 3M Center, Post
Office Box 33427, Saint Paul, MN 55133-3427, US [US,
US], for all designates States except US;
CROOKS, Stephen L., 82 Pine Street, Mahtomedi, MN
55115-1937, US [US, US], for US only;
GRIESGRABER, George W., 631 Crimson Leaf Court, Eagan,
MN 55123, US [US, US], for US only;
HEPPNER, Philip D., 607D Woodduck Drive, Woodbury, MN
55125, US [US, US], for US only;
MERRILL, Bryon A., 8280 1155th Street North, River
Falls, WI 54022, US [US, US], for US only
AGENT: HOWARD, MarySusan\$, Office of Intellectual Property
Counsel, Post Office Box 33427, Saint Paul, MN
55133-3427\$, US

LANGUAGE OF FILING:

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002046188	A2	20020613

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW
GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (ARIPO): AM AZ BY KG KZ MD RU TJ TM

RW (EAPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR

RW (OAPI): BF BJ CF CG CI CM GA GN GO GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US46359 A 20011206

PRIORITY INFO.: US 2000-60/254,218 20001208

L29 ANSWER 4 OF 5

ACCESSION NUMBER: 2000040228 PCTFULL ED 20020515

TITLE (ENGLISH): FORMULATIONS AND METHODS FOR TREATMENT OF MUCOSAL
ASSOCIATED CONDITIONS WITH AN IMMUNE RESPONSE MODIFIER
FORMULATIONS ET PROCEDES UTILISES POUR LE TRAITEMENT
DES ETATS PATHOLOGIQUES DES MUQUEUSES AU MOYEN D'UN
MODIFICATEUR DE LA REPONSE IMMUNITAIRE

TITLE (FRENCH):

INVENTOR(S): PHARES, Kenneth;

LI, Jane, Z.;

JOZWIAKOWSKI, Michael, J.;

MILLER, Richard, L.;

SKWIERCZYNISKI, Raymond, D.;

BUSCH, Terri, F.

PATENT ASSIGNEE(S): 3M INNOVATIVE PROPERTIES COMPANY

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000040228	A2	20000713

DESIGNATED STATES

W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE

KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
 NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
 UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM
 AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB
 GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML
 MR NE SN TD TG
 WO 2000-US370 A 20000107
 PRIORITY INFO.: US 1999-60/115,253 19990108

L29 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1998017279 PCTFULL ED 20020514
 TITLE (ENGLISH): IMMUNE RESPONSE MODIFIER COMPOUNDS FOR TREATMENT OF TH2
 MEDiated AND RELATED DISEASES
 TITLE (FRENCH): COMPOSES MODIFICATEURS DE LA REPONSE IMMUNITAIRE POUR
 LE TRAITEMENT DES MALADIES INDUITES PAR LES TH2 OU
 ASSOCIEES
 INVENTOR(S): TOMAI, Mark, A.;
 HAMMERBECK, David, M.;
 SWINGLE, Karl, F.
 PATENT ASSIGNEE(S): MINNESOTA MINING AND MANUFACTURING COMPANY
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9817279	A1	19980430

 DESIGNATED STATES
 W:
 AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR
 LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE
 SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH KE LS MW
 SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK
 ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
 GA GN ML MR NE SN TD TG
 WO 1997-US19990 A 19971024
 PRIORITY INFO.: US 1996-60/029,301 19961025
 US 1997-60/045,331 19970501

=> d ibib kwic 5

L29 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1998017279 PCTFULL ED 20020514
 TITLE (ENGLISH): IMMUNE RESPONSE MODIFIER COMPOUNDS FOR TREATMENT OF TH2
 MEDiated AND RELATED DISEASES
 TITLE (FRENCH): COMPOSES MODIFICATEURS DE LA REPONSE IMMUNITAIRE POUR
 LE TRAITEMENT DES MALADIES INDUITES PAR LES TH2 OU
 ASSOCIEES
 INVENTOR(S): TOMAI, Mark, A.;
 HAMMERBECK, David, M.;
 SWINGLE, Karl, F.
 PATENT ASSIGNEE(S): MINNESOTA MINING AND MANUFACTURING COMPANY
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9817279	A1	19980430

 DESIGNATED STATES
 W:
 AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR
 LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE
 SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH KE LS MW
 SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK
 ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

APPLICATION INFO.: GA GN ML MR NE SN TD TG
WO 1997-US19990 A 19971024
PRIORITY INFO.: US 1996-60/029,301 19961025
US 1997-60/045,331 19970501

ABEN Immune response modifier compounds - imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines - are useful for the treatment of . . .

DETD . . . immunostimulating, antiviral and antitumor activities are discussed in detail, and certain specific diseases are identified as being susceptible to treatment therewith, including basal cell carcinoma, eczema, essential thrombocythaemia, hepatitis B, multiple sclerosis, neoplastic diseases, psoriasis, rheumatoid arthritis, type I herpes simplex, type II herpes simplex, and warts. One of these IRM compounds, known as imiquimod, has been commercialized in a topical formulation, Aldara TM, for the treatment of anogenital warts associated with human papilloma virus.

Particularly preferred IRM compounds include 4-amino ethoxymethyl-(X, (X-dimethyl-I H-imidazo[4,5-c]quinoline- I -ethanol and 1-(2-methylpropyl)- I H-imidazo[4,5-c]quinolin amine (known as Imiquimod).

The first set of studies evaluate the IRM compound 4-amino ethoxymethyl-oc,ot-dimethyl- I H-imidazo[4,5-c]quinoline- I -ethanol for its ability to inhibit . . . day 0 with 10 pg of ovalbumin (OVA) ip in I% alum and then boosted 7 days later with the same regimen. Fourteen days after boosting animals were dosed by nebulization for 30 minutes using a 1% OVA solution. This was repeated on . . .

=> d his

(FILE 'HOME' ENTERED AT 10:15:22 ON 23 MAR 2006)

FILE 'REGISTRY' ENTERED AT 10:15:32 ON 23 MAR 2006
E "IMIQUIMOD"/CN 25

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 10:16:02 ON 23 MAR 2006

L2 310 S L1
L3 1666 S BASAL CELL CARCINOM?
L4 14 S L3 (L) L2
L5 36 S L3 AND L2
L6 472666 S CYCLE OR SCHEDULE OR REGIMENT?
L7 3 S L6 AND L4
L8 3 S L6 AND L5
L9 199 S IMMUNE RESPONSE MODIFIER
L10 20 S L9 (L) L3
L11 1 S L10 AND L6
L12 21 S L9 AND L3

FILE 'MEDLINE' ENTERED AT 10:18:58 ON 23 MAR 2006

L13 677 S IMIQUIMOD
L14 5638 S BASAL CELL CARCINOM?
L15 106 S L14 AND L13
L16 434542 S CYCLE OR SCHEDULE OR REGIMENT?

L17 20 S L16 AND L15
L18 14 S L17 NOT PY>2003
L19 9 S L18 NOT PY>2002

FILE 'PCTFULL' ENTERED AT 10:21:02 ON 23 MAR 2006
L20 485 S IMIQUIMOD
L21 231 S IMMUNE RESPONSE MODIFIER
L22 2869 S BASAL CELL CARCINOM?
L23 37 S L21/AB
L24 28 S L23 AND L22
L25 12 S L24 NOT PY>2002
L26 224802 S CYCLE OR SCHEDULE OR REGIMENT?
L27 11 S L26 AND L25
L28 11 S L27 AND L23
L29 5 S L28 AND L20

=> exit

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.66	46.09
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

STN INTERNATIONAL LOGOFF AT 10:24:13 ON 23 MAR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPSTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 21 IPC search and display fields enhanced in CA/CAplus with the
IPC reform
NEWS 4 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 5 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 6 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 7 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 8 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 9 JAN 30 Saved answer limit increased
NEWS 10 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA
NEWS 11 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 12 FEB 22 Status of current WO (PCT) information on STN
NEWS 13 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 14 FEB 22 Updates in EPFULL; IPC 8 enhancements added